Category Archives: News

Jean Lindemann, co-discoverer of interferon, is dead at 90. Dr. Lindemann's pioneering work revolutionized the way Hepatitis C, some cancers, and multiple sclerosis are treated. His passing comes at the time of the greatest Hepatitis C innovation in a generation. Read more at New York Times.

HCV News Week Ending 01/25/2015 Vertical Transmission of HCV: The Next Big Treatment Frontier 'Novel antiviral therapies with overwhelmingly positive sustained virologic response rates have dominated headlines in hepatitis C virus for the past few years, but many experts said eradication efforts may never completely succeed until the clinical community deals with vertical transmission of…

HCV News Week Ending 01/18/2015 Access to Hepatitis C Therapy Listening Session with Community Stakeholders 'Last month, the Department of Health and Human Services (HHS) convened a listening session on the important issue of access to curative treatment for hepatitis C virus infection. While the advent of more effective, second-generation direct-acting antivirals for the treatment…

HCV News Week Ending 01/04/2015   Viral Hepatitis Issues Examined at 2014 American Public Health Association (APHA) Annual Meeting 'Hepatitis B and C were among the important public health issues examined at the recent annual meeting of the American Public Health Association (APHA) Exit Disclaimer. The annual meeting, held November 14-19, 2014 in New Orleans,…

  HCV News Week Ending 12/28/2014   The Winner of the AbbVie-Gilead Hep-C Battle? Express Scripts 'Leerink's David Larsen and Chris Abbott point to the one definite winner in the battle between Gilead Sciences (GILD) and AbbVie (ABBV) for hepatitis-C supremacy: Express Scripts (ESRX). They explain: "This morning Express Scripts announced that it has struck…

HCV News Week Ending 11/30/2014   Perspective: Incision revision 'Hepatocellular carcinoma (HCC), a form of cancer that begins in the liver, is the second-most-common cause of cancer-related death around the world. HCC is nearly always the result of an underlying chronic liver disease, usually viral hepatitis, and the choice and outcome of treatment depend on…

 HCV News Week Ending 11/23/14 Early access no cure-all for HepC 'It is not often we hear the word 'cure' mentioned in the development of a new class of drug, but the direct-acting antiviral (DAAs) agents for people with the hepatitis C virus (HCV) have that exact potential. Indeed, this revolution in treatment could mean…

 HCV News Week Ending 11/16/14 Medicaid patients denied new hepatitis C cures 'Revolutionary new drugs are curing hepatitis C, halting a disease that can corrode the liver to the point of cirrhosis, cancer and death. But state restrictions on who can get the costly drugs are keeping them out of reach for some of the…

After Being Cured…Can Hep C Return? READ MORE

(Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C is FDA Approved READ NEWS